72,234 articles
Lazarus taxon
A Lazarus taxon, plural Lazarus taxa, is a species or group thought extinct that is later found alive again, a term attributed to paleontologists Karl Flessa and David Jablonski in 1983.
Lazertinib
Lazertinib (YH25448; Leclaza, Lazcluze) is an oral, brain-penetrant third-generation EGFR tyrosine kinase inhibitor for NSCLC, approved in South Korea in 2021 and, with amivantamab, in the US in 2024.
Laziness
Laziness, also called sloth or idleness, is the disinclination to work or expend effort. Not a psychiatric diagnosis; modern research explains it via motivation quality, effort-based decision making, depression, and apathy.
LB2102 (DLL3 CAR-T)
LB2102 (DJI-136) is Legend Biotech's dnTGFBR2-armored, DLL3-targeted autologous CAR-T therapy for ES-SCLC and LCNEC, licensed to Novartis in 2023 for $100M upfront plus up to $1.01B milestones; phase 1 NCT05680922 showed no DLTs and ORR 18%.
LBL-051
LBL-051: first-in-class CD19×BCMA×CD3 trispecific T-cell engager from Nanjing Leads Biolabs' LeadsBody platform, licensed to Aditum Bio spinout Oblenio Bio for autoimmune B-cell depletion; Phase 1a dosing in Europe since August 2026.
LBR
LBR, or lamin B receptor, is a bifunctional protein of the inner nuclear membrane that tethers heterochromatin to the nuclear periphery and acts as a sterol reductase in cholesterol biosynthesis.
LCAT
LCAT (lecithin-cholesterol acyltransferase, EC 2.3.1.43) is the plasma enzyme esterifying cholesterol on HDL, central to reverse cholesterol transport; deficiency causes familial LCAT deficiency and fish-eye disease.
LCAT deficiency
LCAT deficiency (lecithin-cholesterol acyltransferase deficiency), including familial LCAT deficiency (FLD) and fish-eye disease (FED), is a rare autosomal recessive lipoprotein disorder causing corneal opacities, hemolytic anemia, very low HDL-C, and progressive renal failure.
LCC-ICCG
LCC-ICCG is an engineered variant of the leaf-branch compost cutinase enzyme that depolymerizes PET plastic into terephthalic acid and ethylene glycol, serving as a benchmark in enzymatic recycling research.
LCCL domain
LCCL domain (IPR004043): ~100-amino-acid protein module named after Limulus factor C, Coch-5b2 and Lgl1; novel NMR fold, disulfide-bonded, mutated in DFNA9 deafness and present in Plasmodium LAP proteins.
Lck-interacting transmembrane adapter 1
LIME1 (LIME, Lck-interacting membrane protein) is a human chromosome 20q13.33 gene encoding a 295-aa raft-associated transmembrane adaptor linking T-cell and B-cell receptor signaling to Lck and Lyn, distinct from LIMA1 and the LIME explainability method.
LDHB
LDHB (lactate dehydrogenase B, LDH-H) is a human gene at 12p12.1 encoding the H subunit of lactate dehydrogenase, EC 1.1.1.27, which interconverts pyruvate and lactate with NADH/NAD+; mutations cause asymptomatic LDH-B deficiency.
LDIR-CT-AD trial
LDIR-CT-AD (NCT03597360), a 2019 Canadian single-arm pilot trial treating four advanced Alzheimer's dementia patients with repeated 40 mGy brain CT scans, reporting qualitative cognitive improvements and minor quantitative gains.
LDL apheresis
LDL apheresis is an extracorporeal treatment that removes LDL cholesterol and lipoprotein(a) from the blood, used for severe familial hypercholesterolemia uncontrolled by drugs, with sessions repeated weekly or biweekly.
LDR2402
LDR2402 is an investigational small interfering RNA drug for mild to moderate hypertension, developed by Leaderna Therapeutics, a subsidiary of China's HitGen, now in phase 2.
Le Fort fracture of skull
Le Fort fracture of skull: bilateral midface fracture separating facial skeleton from cranial base; types I (horizontal), II (pyramidal), III (craniofacial dissociation); pterygoid plate fracture unifies all; from René Le Fort's 1901 cadaver experiments.
Le Fort Osteotomy
Le Fort osteotomy: surgical cuts of the maxilla along René Le Fort's 1901 fracture lines (Le Fort I, II, III). Le Fort I repositions the tooth-bearing maxilla for malocclusion, sleep apnea, and midface deficiency; complications about 6.4%.
Le Kang
Le Kang (康乐) is a Chinese ecological genomicist and CAS Distinguished Professor at the Institute of Zoology in Beijing, known for three decades of work on locust genomes and swarming.
Lead extraction (cardiology)
Lead extraction is the percutaneous removal of a pacemaker or defibrillator lead implanted for more than one year, using locking stylets, sheaths, or laser energy, most often for infection.
Lead implantation (cardiology)
Lead implantation is the cardiology procedure of placing insulated electrode wires into the heart chambers and connecting them to a pacemaker, ICD, or CRT pulse generator.
Lead poisoning
Lead poisoning, also called lead toxicity, is the toxic condition caused by absorption of lead into blood and tissues, particularly harmful to young children and women of child-bearing age.
LEAD-1 trial
LEAD-1 SU (NCT00318422), first trial of the LEAD liraglutide phase 3 program: 26-week, five-arm trial adding liraglutide 0.6–1.8 mg, rosiglitazone, or placebo to glimepiride in 1041 type 2 diabetes patients; HbA1c fell 1.1% with higher doses.
LEAD-2 trial
LEAD-2 (NCT00318461) trial: 26-week phase-III randomized trial by Nauck et al. testing liraglutide 0.6–1.8 mg added to metformin versus glimepiride or placebo in 1,091 type 2 diabetes patients; HbA1c −1.0%, weight loss, low hypoglycemia.
LEAD-3 trial
LEAD-3 (LEAD-3 Mono, NCT00294723) is a phase III trial comparing liraglutide 1.2 and 1.8 mg with glimepiride 8 mg monotherapy in 746 patients with early type 2 diabetes over 52 weeks plus a 2-year extension, showing greater HbA1c, weight, and blood pressure benefits with liraglutide.
LEAD-4 trial
LEAD-4 (NCT00333151), a Novo Nordisk phase 3 trial in the LEAD program, tested liraglutide 1.2 or 1.8 mg versus placebo added to metformin plus rosiglitazone in 533 type 2 diabetes patients over 26 weeks.
LEAD-5 trial
LEAD-5 (LEAD-5 met+SU), NCT00331851, a 26-week Novo Nordisk-funded trial comparing liraglutide 1.8 mg with placebo and insulin glargine added to metformin and glimepiride in 581 type 2 diabetes patients across 107 centers in 17 countries.
LEAD-6 trial
LEAD-6 (Liraglutide Effect and Action in Diabetes 6, NCT00518882) was a 2009 Lancet-published 26-week open-label trial comparing liraglutide 1.8 mg once daily with exenatide 10 µg twice daily in type 2 diabetes; liraglutide cut HbA1c more (−1.12% vs −0.79%) with less nausea and hypoglycemia.
Leaden paralysis
Leaden paralysis is the sensation of arms or legs feeling heavy as lead during depressive episodes; a DSM-IV atypical features specifier criterion and ICD-11 term, not true muscular paralysis, linked to bipolar and chronic atypical depression.
LEADER® trial
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), NCT01179048: randomized double-blind trial of liraglutide 1.8 mg daily vs placebo in 9,340 high-risk type 2 diabetes patients; MACE HR 0.87, reduced CV and all-cause death.
LEADERS trial
LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial: 1,707-patient randomized noninferiority trial comparing biodegradable-polymer biolimus-eluting stents with durable-polymer sirolimus-eluting stents; noninferior at 9 months, fewer very late stent thromboses at 5 years.